Home » Stocks » APTX

Aptinyx Inc. (APTX)

Stock Price: $4.07 USD -0.26 (-6.00%)
Updated Jan 20, 2021 1:57 PM EST - Market open
Market Cap 273.90M
Revenue (ttm) 2.48M
Net Income (ttm) -52.34M
Shares Out 46.98M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $4.07
Previous Close $4.33
Change ($) -0.26
Change (%) -6.00%
Day's Open 4.50
Day's Range 3.93 - 4.52
Day's Volume 4,378,664
52-Week Range 1.81 - 5.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Business Wire - 2 weeks ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Business Wire - 2 weeks ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Business Wire - 4 weeks ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Business Wire - 1 month ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Seeking Alpha - 2 months ago

Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Business Wire - 2 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatme...

Business Wire - 2 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Benzinga - 2 months ago

The market's skepticism around Aptinyx Inc's (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymo...

The Motley Fool - 2 months ago

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Other stocks mentioned: SELB, VBIV
Business Wire - 2 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

The Motley Fool - 2 months ago

Investors reacted negatively to the company's announcement of a secondary stock offering.

Business Wire - 2 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

InvestorPlace - 3 months ago

APTX stock is soaring on Tuesday after Aptinyx announced very positive results from its trial for a treatment for those with PTSD. The post Aptinyx News: Why APTX Stock Is Skyrocketing Today a...

The Motley Fool - 3 months ago

The biotech's PTSD drug hit the mark in a midstage trial.

Zacks Investment Research - 3 months ago

Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.

Market Watch - 3 months ago

Shares of Aptinyx Inc. shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the biopharmaceutical company reported positive results...

Business Wire - 3 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Business Wire - 3 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Business Wire - 4 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

24/7 Wall Street - 5 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CBAY, EOLS, IBIO, SIEN
Seeking Alpha - 5 months ago

Aptinyx Inc (APTX) CEO Norbert Riedel on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 6.90% and -41.94%, respectively, for the quarter ended June 2020.

Business Wire - 5 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

Zacks Investment Research - 5 months ago

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Business Wire - 5 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

Business Wire - 5 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

Business Wire - 6 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Business Wire - 6 months ago

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disor...

Seeking Alpha - 6 months ago

Aptinyx PTSD Trial And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 7 months ago

Data readout expected by late 2020 Data readout expected by late 2020

Zacks Investment Research - 7 months ago

Is (APTX) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Aptinyx.

Seeking Alpha - 8 months ago

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of -3.03% and -9.61%, respectively, for the quarter ended March 2020.

GlobeNewsWire - 8 months ago

Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020

Zacks Investment Research - 8 months ago

Aptinyx Inc (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 6th

Other stocks mentioned: ASC, LNG
Zacks Investment Research - 8 months ago

Relative underperformance compared to the large caps, a super-dovish Fed and the U.S. government's gigantic aid toward small-and-mid-cap stocks have boosted pint-sized stocks lately.

Other stocks mentioned: AIRG, TMQ, TUFN, VERI
Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor Aptinyx

Zacks Investment Research - 9 months ago

Aptinyx Inc. (APTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Seeking Alpha - 9 months ago

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 30.51% and -2.96%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 9 months ago

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 11 months ago

NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated with Parkinson’s disease NYX-458 is currently under evaluation in a Phase 2 study...

The Motley Fool - 1 year ago

Shares rose in response to news that a large investment management company has purchased a significant ownership position.

Benzinga - 1 year ago

Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases.

Other stocks mentioned: LJPC, OSMT
GlobeNewsWire - 1 year ago

EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and ne...

About APTX

Aptinyx, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to tr... [Read more...]

Industry
Biotechnology
IPO Date
Jun 21, 2018
CEO
Dr. Norbert G. Riedel
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
APTX
Full Company Profile

Financial Performance

In 2019, Aptinyx's revenue was $3.67 million, a decrease of -44.19% compared to the previous year's $6.57 million. Losses were -$57.41 million, 7.75% more than in 2018.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Aptinyx stock is "Buy." The 12-month stock price forecast is 10.71, which is an increase of 163.14% from the latest price.

Price Target
$10.71
(163.14% upside)
Analyst Consensus: Buy